News

Vetigenics is transforming the treatment of challenging diseases in pets with innovative technology that generates best-in-class antibody therapies.

Pet biotech establishes board of directors, looks ahead to therapies for autoimmune disease, obesity and allergy.

In 2018, at the height of the chimeric antigen receptor T-cell therapy revolution and in the heart of its implementation,...

Vetigenics believes it’s found a way to make pricey antibody-based technologies more accessible for animals. Read More

Animal Health | Headline Analysis US start-up Vetigenics has commenced its pilot clinical trial for a canine anti-cPD1 monoclonal antibody....

Two fully funded pilot studies to treat cancer free for pet owners who bring their dogs to research sites. PHILADELPHIA,...

US pet therapeutics start-up Vetigenics is seeing increased interest from potential collaborators in its Canibody. Adriann Sax, the co-founder and...

Given that dogs are widely regarded as ‘man’s best friend’, it makes sense that we are constantly striving to find...